Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study

Trial Profile

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Sintilimab (Primary)
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ORIENT-1
  • Sponsors Innovent Biologics
  • Most Recent Events

    • 05 Jun 2018 According to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology, patients were enrolled in this study between 30th Mar 2017 and 1st Nov 2017.
    • 05 Jun 2018 Results (data cut off: 8 feb, 2018; n=96) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 According to an Innovent Biologics media release, the new drug application (NDA) for IBI308 for the treatment of relapsed/refractory classical Hodgkin Lymphoma was officially accepted by the Center of Drug Evaluation of the China Food and Drug Administration (CFDA) on April 19, 2018 and was granted the Priority Review Status on April 23, 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top